LifeStance Health Group, Inc. (NASDAQ:LFST) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. raised its position in LifeStance Health Group, Inc. (NASDAQ:LFST) by 124.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,828 shares of the company’s stock after purchasing an additional 2,122 shares during the quarter. Blue Trust Inc.’s holdings in LifeStance Health Group were worth $27,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in LFST. Townsquare Capital LLC bought a new position in LifeStance Health Group in the 3rd quarter worth approximately $73,000. R Squared Ltd bought a new position in shares of LifeStance Health Group in the fourth quarter worth $80,000. Entropy Technologies LP bought a new position in shares of LifeStance Health Group in the fourth quarter worth $150,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of LifeStance Health Group by 31.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,105 shares of the company’s stock valued at $169,000 after purchasing an additional 5,767 shares during the period. Finally, Paloma Partners Management Co bought a new stake in shares of LifeStance Health Group during the third quarter valued at about $176,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Trading Up 3.1 %

Shares of LFST stock opened at $7.74 on Friday. The stock has a 50-day simple moving average of $7.79 and a 200 day simple moving average of $7.21. The stock has a market capitalization of $2.96 billion, a P/E ratio of -29.77 and a beta of 1.28. LifeStance Health Group, Inc. has a fifty-two week low of $4.64 and a fifty-two week high of $9.20. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LFST. The Goldman Sachs Group upgraded shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Monday, December 16th. Barclays increased their price objective on shares of LifeStance Health Group from $6.00 to $7.00 and gave the company an “underweight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.70.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.